collection
MENU ▼
Read by QxMD icon Read
search

NOAC

shared collection
25 papers 100 to 500 followers Review of warfarin in AF
https://www.readbyqxmd.com/read/23810130/management-of-major-bleeding-complications-and-emergency-surgery-in-patients-on-long-term-treatment-with-direct-oral-anticoagulants-thrombin-or-factor-xa-inhibitors-proposals-of-the-working-group-on-perioperative-haemostasis-gihp-march-2013
#1
Gilles Pernod, Pierre Albaladejo, Anne Godier, Charles M Samama, Sophie Susen, Yves Gruel, Normand Blais, Pierre Fontana, Ariel Cohen, Juan V Llau, Nadia Rosencher, Jean-François Schved, Emmanuel de Maistre, Meyer M Samama, Patrick Mismetti, Pierre Sié
Direct new oral anticoagulants (NOACs) - inhibitors of thrombin or factor Xa - are intended to be used largely in the treatment of venous thromboembolic disease or the prevention of systematic embolism in atrial fibrillation, instead of vitamin K antagonists. Like any anticoagulant treatment, they are associated with spontaneous or provoked haemorrhagic risk. Furthermore, a significant proportion of treated patients are likely to be exposed to emergency surgery or invasive procedures. Given the absence of a specific antidote, the action to be taken in these situations must be defined...
June 2013: Archives of Cardiovascular Diseases
https://www.readbyqxmd.com/read/25650285/venous-thromboembolism-in-the-elderly-efficacy-and-safety-of-non-vka-oral-anticoagulants
#2
REVIEW
Vincent Geldhof, Christophe Vandenbriele, Peter Verhamme, Thomas Vanassche
Increasing age and renal impairment are risk factors for venous thrombosis but also for anticoagulant-induced bleeding. In large-scale phase III trials, non-VKA oral anticoagulants (NOACs) were at least as effective and safe for the treatment of acute venous thromboembolism as warfarin. Here, we review the efficacy and safety of dabigatran, rivaroxaban, apixaban and edoxaban in the subgroups of elderly patients (≥75 years) and patients with impaired renal function (creatinine clearance ≤50 ml/min). In all phase III trials, the efficacy of NOACs in the prevention of recurrent VTE was conserved both in the elderly subgroup and in the subgroup with impaired renal function...
2014: Thrombosis Journal
https://www.readbyqxmd.com/read/24548437/warfarin-and-atrial-fibrillation-from-ideal-to-real-the-warfarin-affaire
#3
Mauro Molteni, Claudio Cimminiello
Vitamin K Antagonists (VKAs) are widely used in clinical practice and nearly 1% of the entire population receives oral anticoagulation at least once in life. However, the rate of prescription of anticoagulation is low, compared to what it should be. No more than 50-60% of patients affected by atrial fibrillation (AF) receive anticoagulation. In the setting of AF, VKAs are safe and effective when properly managed, reducing stroke and systemic embolism by more than 60%. VKAs safety and effectiveness are closely related to the quality of anticoagulation (e...
2014: Thrombosis Journal
https://www.readbyqxmd.com/read/24455237/dabigatran-rivaroxaban-or-apixaban-versus-warfarin-in-patients-with-nonvalvular-atrial-fibrillation-a-systematic-review-and-meta-analysis-of-subgroups
#4
REVIEW
Antonio Gómez-Outes, Ana Isabel Terleira-Fernández, Gonzalo Calvo-Rojas, M Luisa Suárez-Gea, Emilio Vargas-Castrillón
Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have become available as an alternative to warfarin anticoagulation in non-valvular atrial fibrillation (NVAF). Methods. MEDLINE and CENTRAL, regulatory agencies websites, clinical trials registers and conference proceedings were searched to identify randomised controlled trials of NOAC versus warfarin in NVAF. Two investigators reviewed all studies and extracted data on patient and study characteristics along with cardiovascular outcomes...
2013: Thrombosis
https://www.readbyqxmd.com/read/23953909/new-oral-anticoagulants-in-elderly-patients
#5
REVIEW
Stefano Barco, Yuk Wah Cheung, John W Eikelboom, Michiel Coppens
The new oral anticoagulants (NOACs) dabigatran etexilate, rivaroxaban, and apixaban have been extensively studied for prevention and treatment of venous thromboembolic disease and for stroke prevention in atrial fibrillation. Elderly patients have the highest incidence of thrombotic complications but also have the highest risk of anticoagulant associated bleeding. In this review we critically examine the balance between risks and benefits of NOACs compared with vitamin K antagonists in elderly patients enrolled in phase 3 randomized controlled trials for the management of venous thrombosis and stroke prevention in atrial fibrillation...
June 2013: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/23953908/new-developments-in-parenteral-anticoagulation-for-arterial-and-venous-thromboembolism
#6
REVIEW
Nick van Es, Suzanne M Bleker, Harry R Büller, Michiel Coppens
The efficacy and safety of heparin and low-molecular-weight heparins (LMWHs) are well documented in venous and arterial thromboembolism. Several drawbacks of heparins have inspired the development of newer parenteral anticoagulants for specific indications, including heparin-induced thrombocytopenia (HIT) and percutaneous coronary interventions (PCI). The direct thrombin inhibitors recombinant hirudin and argatroban are now established alternatives for HIT patients, and bivalirudin is one of the most used anticoagulants in PCI...
June 2013: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/23937286/clinical-use-of-new-oral-anticoagulant-drugs-dabigatran-and-rivaroxaban
#7
REVIEW
Trevor Baglin
Orally active small molecules that selectively and specifically inhibit coagulation serine proteases have been developed for clinical use. For some patients these oral direct inhibitors (ODIs) offer substantial benefits over oral vitamin K antagonists (VKA). However, for the majority of patients with good anticoagulant control with VKAs the advantages of the ODIs are primarily convenience and few drug interactions. The drugs are prescribed at fixed dose without the need for monitoring or dose adjustment in the majority of patients and the rapid onset of anticoagulation and short half-life make initiation and interruption of anticoagulation considerably easier than with VKAs...
October 2013: British Journal of Haematology
https://www.readbyqxmd.com/read/23822763/laboratory-assessment-of-rivaroxaban-a-review
#8
Meyer Michel Samama, Geneviève Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem, Céline Guinet, Yves Gourmelin, Gabriele Rohde, Jean-Luc Martinoli
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases thrombin generation. Based on the results of phase III clinical trials, rivaroxaban, a direct Factor Xa inhibitor, has been approved in many countries for the management of several thromboembolic disorders. Owing to its predictable pharmacokinetic and pharmacodynamic characteristics, fixed-dose regimens are used without the need for routine coagulation monitoring...
2013: Thrombosis Journal
https://www.readbyqxmd.com/read/23808982/oral-apixaban-for-the-treatment-of-acute-venous-thromboembolism
#9
RANDOMIZED CONTROLLED TRIAL
Giancarlo Agnelli, Harry R Buller, Alexander Cohen, Madelyn Curto, Alexander S Gallus, Margot Johnson, Urszula Masiukiewicz, Raphael Pak, John Thompson, Gary E Raskob, Jeffrey I Weitz
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism...
August 29, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/23807375/rivaroxaban-for-the-treatment-of-pulmonary-embolism
#10
REVIEW
Thomas Vanassche, Peter Verhamme
With the advent of new oral anticoagulants (NOACs) for the treatment of deep-vein thrombosis (DVT) and/or pulmonary embolism (PE), a new era of oral anticoagulation for patients with venous thromboembolism (VTE) has begun. Rivaroxaban is the first NOAC to receive regulatory approval for the acute and continued treatment of DVT and PE, and for the secondary prevention of VTE. Here, the clinical trials of rivaroxaban in patients with VTE are reviewed, and the clinical use of rivaroxaban for patients with PE is discussed...
June 2013: Advances in Therapy
https://www.readbyqxmd.com/read/23691304/new-oral-anticoagulants-in-the-treatment-of-pulmonary-embolism-efficacy-bleeding-risk-and-monitoring
#11
Kelly M Rudd, Elizabeth Lisa M Phillips
Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent significant morbidity and mortality. The mainstay of therapy has been vitamin-K antagonist therapy bridged with parenteral anticoagulants. The recent approval of new oral anticoagulants (NOACs: apixaban, dabigatran, and rivaroxaban) has generated significant interest in their role in managing venous thromboembolism, especially pulmonary embolism due to their improved pharmacokinetic and pharmacodynamic profiles, predictable anticoagulant response, and lack of required efficacy monitoring...
2013: Thrombosis
https://www.readbyqxmd.com/read/23625209/ehra-practical-guide-on-the-use-of-new-oral-anticoagulants-in-patients-with-non-valvular-atrial-fibrillation-executive-summary
#12
Hein Heidbuchel, Peter Verhamme, Marco Alings, Matthias Antz, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A John Camm, Paulus Kirchhof
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in specific clinical situations. This text is an executive summary of a practical guide that the European Heart Rhythm Association (EHRA) has assembled to help physicians in the use of the different NOACs. The full text is being published in EP Europace. Practical answers have been formulated for 15 concrete clinical scenarios: (i) practical start-up and follow-up scheme for patients on NOACs; (ii) how to measure the anticoagulant effect of NOACs; (iii) drug-drug interactions and pharmacokinetics of NOACs; (iv) switching between anticoagulant regimens; (v) ensuring compliance of NOAC intake; (vi) how to deal with dosing errors; (vii) patients with chronic kidney disease; (viii) what to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a risk of bleeding?; (ix) management of bleeding complications; (x) patients undergoing a planned surgical intervention or ablation; (xi) patients undergoing an urgent surgical intervention; (xii) patients with AF and coronary artery disease; (xiii) cardioversion in a NOAC-treated patient; (xiv) patients presenting with acute stroke while on NOACs; (xv) NOACs vs...
July 2013: European Heart Journal
https://www.readbyqxmd.com/read/23564912/the-laboratory-and-the-direct-oral-anticoagulants
#13
REVIEW
Armando Tripodi
Although direct oral anticoagulants do not need laboratory testing for dose adjustment, there are instances when laboratory measurement of the drug anticoagulant effect may be useful. They include before initiation of treatment, before surgical or invasive procedures, on the occasion of hemorrhagic or thrombotic events, and whenever immediate reversal of anticoagulation is needed. Choice of tests should be primarily based on their prompt availability. Accordingly, the dilute-thrombin or the ecarin clotting times are best suited for dabigatran and the prothrombin time or the anti-FXa for rivaroxaban...
May 16, 2013: Blood
https://www.readbyqxmd.com/read/23484796/dabigatran-and-postmarketing-reports-of-bleeding
#14
Mary Ross Southworth, Marsha E Reichman, Ellis F Unger
In the months following the approval of the oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) in October 2010, the Food and Drug Administration (FDA) received through the FDA Adverse Event Reporting System (FAERS) many reports of serious and fatal bleeding events associated with use of..
April 4, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/23476049/a-specific-antidote-for-dabigatran-functional-and-structural-characterization
#15
Felix Schiele, Joanne van Ryn, Keith Canada, Corey Newsome, Eliud Sepulveda, John Park, Herbert Nar, Tobias Litzenburger
Dabigatran etexilate is a direct thrombin inhibitor and used widely as an anticoagulant for the prevention of stroke in patients with atrial fibrillation. However, anticoagulation therapy can be associated with an increased risk of bleeding. Here, we present data on the identification, humanization, and in vitro pharmacology of an antidote for dabigatran (aDabi-Fab). The X-ray crystal structure of dabigatran in complex with the antidote reveals many structural similarities of dabigatran recognition compared with thrombin...
May 2, 2013: Blood
https://www.readbyqxmd.com/read/23470618/new-oral-anticoagulants-increase-risk-for-gastrointestinal-bleeding-a-systematic-review-and-meta-analysis
#16
COMMENT
I Lisanne Holster, Vera E Valkhoff, Ernst J Kuipers, Eric T T L Tjwa
BACKGROUND & AIMS: A new generation of oral anticoagulants (nOAC), which includes thrombin and factor Xa inhibitors, has been shown to be effective, but little is known about whether these drugs increase patients' risk for gastrointestinal bleeding (GIB). Patients who require OAC therapy frequently have significant comorbidities and may also take aspirin and/or thienopyridines. We performed a systematic review and meta-analysis of the risk of GIB and clinically relevant bleeding in patients taking nOAC...
July 2013: Gastroenterology
https://www.readbyqxmd.com/read/23425163/extended-use-of-dabigatran-warfarin-or-placebo-in-venous-thromboembolism
#17
RANDOMIZED CONTROLLED TRIAL
Sam Schulman, Clive Kearon, Ajay K Kakkar, Sebastian Schellong, Henry Eriksson, David Baanstra, Anne Mathilde Kvamme, Jeffrey Friedman, Patrick Mismetti, Samuel Z Goldhaber
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1...
February 21, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/23419049/selection-and-assessment-of-patients-treated-with-the-novel-oral-anticoagulant-drugs-a-recommendation-from-the-subcommittee-on-control-of-anticoagulation-of-the-scientific-and-standardisation-committee-of-the-international-society-on-thrombosis-and-haemostasis
#18
https://www.readbyqxmd.com/read/23220847/acute-management-of-bleeding-in-patients-on-novel-oral-anticoagulants
#19
REVIEW
Deborah M Siegal, Mark A Crowther
Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently available for prevention of venous thromboembolism (VTE) after orthopaedic surgery, treatment of acute VTE, and prevention of arterial thromboembolism in non-valvular atrial fibrillation. These agents offer advantages over VKAs, including rapid onset, shorter half-lives, fewer drug interactions, and lack of need for routine monitoring. However, there are no established agents to reverse their anticoagulant effect...
February 2013: European Heart Journal
https://www.readbyqxmd.com/read/23216615/apixaban-for-extended-treatment-of-venous-thromboembolism
#20
RANDOMIZED CONTROLLED TRIAL
Giancarlo Agnelli, Harry R Buller, Alexander Cohen, Madelyn Curto, Alexander S Gallus, Margot Johnson, Anthony Porcari, Gary E Raskob, Jeffrey I Weitz
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy...
February 21, 2013: New England Journal of Medicine
label_collection
label_collection
1471
1
2
2014-03-31 13:18:29
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"